Press Releases - Notch Therapeutics

News & Events >

PRESS RELEASES.

March 28, 2023
Notch Therapeutics Promotes Chris Bond to Chief Scientific Officer

February 27, 2023
Notch Researchers Develop Improved Model for Predicting CAR-T Clinical Pharmacology and Response to Advance Next-Generation Product Design; Results Published in Nature Biotechnology

November 8, 2022
Notch Therapeutics Enhances Cell Therapy Expertise with Updates to Scientific Advisory Board

September 14, 2022
University of British Columbia Research Team Develops Accelerated Process for Producing T Cells from Human Stem Cells for Manufacturing Cell Therapies; Advancement Enhances Notch Technology Platform

April 6, 2022
Notch Therapeutics Welcomes Deepika Rajesh as VP, Stem Cell Biology & Developmental Immunology

January 6, 2022
Notch Therapeutics’ Peter Zandstra Appointed to the Order of Canada

August 18, 2021
Notch Therapeutics Scientific Co-Founder Recognized in Nature Communications Publication Describing the Company’s Foundational Technology for Generating T Cells from Renewable Sources

August 6, 2021
Notch Therapeutics Named 2021 Emerging Life Sciences Company of the Year by Life Sciences BC

June 18, 2021
Notch Therapeutics Participates as Sponsor and Presenter at ISSCR 2021 Virtual Meeting

February 10, 2021
Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

January 25, 2021
Notch Therapeutics Appoints Cellular Immunotherapy Veteran Chris Bond, Ph.D. as SVP, Preclinical and Translational Sciences

October 19, 2020
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development

July 20, 2020
Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company’s Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics

November 5, 2019
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Others